Select Publications
Book Chapters
2015, 'Glutamine and glucagon-like peptide-1 response', in Rajendram R; Preedy VR; Patel VB (ed.), Glutamine in Clinical Nutrition, Springer, London
,Journal articles
2024, 'Effect of denosumab on inflammation and bone health in active Charcot foot: A phase II randomised controlled trial', Journal of Diabetes and its Complications, 38, http://dx.doi.org/10.1016/j.jdiacomp.2024.108718
,2024, 'Classification of type 1 diabetes: A pathogenic and treatment-based classification.', Diabetes Metab Syndr, 18, pp. 102986, http://dx.doi.org/10.1016/j.dsx.2024.102986
,2024, 'Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists', Medical Journal of Australia, 220, pp. 14 - 16, http://dx.doi.org/10.5694/mja2.52170
,2024, 'Fournier’s gangrene in recent transplant recipient on empagliflozin', JHLT Open, 4, pp. 100060 - 100060, http://dx.doi.org/10.1016/j.jhlto.2024.100060
,2023, 'Delayed Gastric Emptying with Perioperative Use of Glucagon-like Peptide-1 Receptor Agonists', American Journal of Medicine, 136, pp. e233 - e234, http://dx.doi.org/10.1016/j.amjmed.2023.07.016
,2023, 'Effects of bariatric surgery and dietary intervention on insulin resistance and appetite hormones over a 3 year period', Scientific Reports, 13, http://dx.doi.org/10.1038/s41598-023-33317-6
,2023, 'Sodium-Glucose Cotransporter 2 Inhibitor-Associated “Ketoacidosis” Versus “Diabetic Ketoacidosis”: The Importance of Accurate Terminology', Drug Safety, 46, pp. 1303 - 1305, http://dx.doi.org/10.1007/s40264-023-01358-5
,2023, 'Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in bridge-to-transplant patients supported with centrifugal-flow left ventricular assist devices', International Journal of Cardiology, 391, http://dx.doi.org/10.1016/j.ijcard.2023.131259
,2023, 'SGLT2 Inhibitor-Induced Ketoacidosis in a Patient Without Diabetes', Diabetes Care, 47, pp. e4 - e5, http://dx.doi.org/10.2337/dc23-1903
,2023, 'Peri-procedural ketoacidosis risk with sodium-glucose cotransporter 2 inhibitor use in people without diabetes', Anaesthesia, 78, pp. 1418 - 1419, http://dx.doi.org/10.1111/anae.16068
,2023, 'OR18-03 Peripheral But Not Hepatic Insulin Resistance Associates With Adverse Vascular And Metabolic Health In Type 1 Diabetes: A Possible Target For Adjunctive Therapy', Journal of the Endocrine Society, 7, http://dx.doi.org/10.1210/jendso/bvad114.895
,2023, 'THU298 Effect Of SGLT2 Inhibition On Metabolic, Cardiac And Renal Outcomes In Heart Transplant Recipients (EMPA-HTx study): Protocol And Study Design', Journal of the Endocrine Society, 7, http://dx.doi.org/10.1210/jendso/bvad114.733
,2023, 'Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes', Medical Journal of Australia, 219, pp. 293 - 294, http://dx.doi.org/10.5694/mja2.52067
,2023, 'Associations of Type 2 Diabetes, Body Composition, and Insulin Resistance with Bone Parameters: The Dubbo Osteoporosis Epidemiology Study', JBMR Plus, 7, http://dx.doi.org/10.1002/jbm4.10780
,2023, 'Metabolic Sequelae of Everolimus Treatment After Cardiac Transplant: A Hypothesis-Generating Study', Heart Lung and Circulation, 32, pp. 1076 - 1079, http://dx.doi.org/10.1016/j.hlc.2023.05.014
,2023, 'Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)', European Journal of Clinical Pharmacology, 79, pp. 1239 - 1248, http://dx.doi.org/10.1007/s00228-023-03539-8
,2023, 'The safe use of metformin in heart failure patients both with and without T2DM: A cross-sectional and longitudinal study', British Journal of Clinical Pharmacology, 89, pp. 2603 - 2613, http://dx.doi.org/10.1111/bcp.15737
,2023, '1438-P: Diabetes after Cardiac Transplant with Low-Dose Everolimus and Tacrolimus', Diabetes, 72, http://dx.doi.org/10.2337/db23-1438-p
,2023, 'Response to the Letter to the Editor regarding “Contribution of peripheral neuropathy to poor bone health in the feet of people with type 2 diabetes mellitus”', Acta Diabetologica, 60, pp. 713 - 714, http://dx.doi.org/10.1007/s00592-023-02052-9
,2023, 'Diabetes medication following heart transplantation: a focus on novel cardioprotective therapies—a joint review from endocrinologists and cardiologists', Acta Diabetologica, 60, pp. 471 - 480, http://dx.doi.org/10.1007/s00592-022-02018-3
,2023, 'Safety and Tolerability of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients Supported with Left Ventricular Assist Devices', JOURNAL OF HEART AND LUNG TRANSPLANTATION, 42, pp. S450 - S451, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000992480601267&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2023, 'Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): Protocol for a randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-069641
,2023, 'Olanzapine-induced multifactorial chylomicronaemia syndrome: a rare but important complication', ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2023, http://dx.doi.org/10.1530/EDM-22-0225
,2023, '‘We are somehow fixated on this being a diabetes drug’: a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.16203
,2023, 'Contributors to impaired bone health in type 2 diabetes', Trends in Endocrinology and Metabolism, 34, pp. 34 - 48, http://dx.doi.org/10.1016/j.tem.2022.11.003
,2023, 'Once-Weekly Semaglutide in Adolescents with Obesity', New England Journal of Medicine, 388, pp. 1145, http://dx.doi.org/10.1056/NEJMc2300510
,2023, 'Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.16312
,2023, 'Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes.', JCEM Case Rep, 1, pp. luac017, http://dx.doi.org/10.1210/jcemcr/luac017
,2022, 'Metabolomics and Lipidomics Signatures of Insulin Resistance and Abdominal Fat Depots in People Living with Obesity', Metabolites, 12, http://dx.doi.org/10.3390/metabo12121272
,2022, 'Tip of the iceberg: are we missing undiagnosed patients with maturity onset diabetes of the young?', Internal Medicine Journal, 52, pp. 2011 - 2012, http://dx.doi.org/10.1111/imj.15948
,2022, 'Immunophenotype and genetic risk scores to improve autoantibody negative type 1 diabetes classification: study protocol', International Journal of Clinical Trials, 9, pp. 293 - 293, http://dx.doi.org/10.18203/2349-3259.ijct20222690
,2022, 'Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction', Internal Medicine Journal, 52, pp. 1666 - 1676, http://dx.doi.org/10.1111/imj.15727
,2022, 'Hyperglycaemia induced by gamma-butyrolactone', Diabetic Medicine, 39, http://dx.doi.org/10.1111/dme.14850
,2022, 'Sodium–glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?', Medical Journal of Australia, 217, pp. 126 - 128, http://dx.doi.org/10.5694/mja2.51637
,2022, 'Effects of bariatric surgery and dietary intervention on changes in insulin resistance and appetite hormones over the period of 3 years', Endocrine Abstracts, http://dx.doi.org/10.1530/endoabs.81.rc5.6
,2022, 'Assessment and treatment of osteoporosis and fractures in type 2 diabetes', Trends in Endocrinology and Metabolism, 33, pp. 333 - 344, http://dx.doi.org/10.1016/j.tem.2022.02.006
,2022, 'Letter to the Editor From Raven et al: "Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine"', Journal of Clinical Endocrinology and Metabolism, 107, pp. E1767 - E1768, http://dx.doi.org/10.1210/clinem/dgab822
,2022, 'Contribution of peripheral neuropathy to poor bone health in the feet of people with type 2 diabetes mellitus', Acta Diabetologica, 59, pp. 217 - 224, http://dx.doi.org/10.1007/s00592-021-01803-w
,2022, 'Voriconazole-Associated Periostitis: New Insights into Pathophysiology and Management', JBMR Plus, 6, http://dx.doi.org/10.1002/jbm4.10557
,2022, 'The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson's disease: A systematic review and meta-analysis', Clinical Parkinsonism and Related Disorders, 6, http://dx.doi.org/10.1016/j.prdoa.2022.100133
,2022, 'Prescribing of SGLT2 Inhibitors in Clinical Practice: A Qualitative Study of Cardiologists', Heart, Lung and Circulation, 31, pp. S96 - S97, http://dx.doi.org/10.1016/j.hlc.2022.06.117
,2022, 'Safety and Tolerability of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients Supported With Left Ventricular Assist Devices', Heart, Lung and Circulation, 31, pp. S100 - S100, http://dx.doi.org/10.1016/j.hlc.2022.06.124
,2021, 'Metabolic dysfunction-associated fatty liver disease and insulin resistance in type 1 diabetes', The Lancet Gastroenterology and Hepatology, 6, pp. 985 - 986, http://dx.doi.org/10.1016/S2468-1253(21)00343-5
,2021, 'Yap regulates skeletal muscle fatty acid oxidation and adiposity in metabolic disease', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-23240-7
,2021, 'Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists', Diabetes Research and Clinical Practice, 180, http://dx.doi.org/10.1016/j.diabres.2021.109036
,2021, 'Role of pancreatic stellate cell-derived exosomes in pancreatic cancer-related diabetes: A novel hypothesis', Cancers, 13, http://dx.doi.org/10.3390/cancers13205224
,2021, 'Effect of fasting ketosis and type 1 diabetes on alcohol breath analysis technology used in Australia', Internal Medicine Journal, 51, pp. 1555 - 1556, http://dx.doi.org/10.1111/imj.15488
,2021, 'Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial', Diabetic Medicine, 38, http://dx.doi.org/10.1111/dme.14564
,2021, 'Prescribing of SGLT2 Inhibitors in Primary Care: A Qualitative Study of Primary Care Physicians and Endocrinologists', DIABETES, 70, http://dx.doi.org/10.2337/db21-779-P
,